Omniome Closes $60 Million Series C Financing To Advance Novel Genomic Sequencing PlatformHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Omniome Closes $60 Million Series C Financing To Advance Novel Genomic Sequencing PlatformPR NewswireJanuary 9, 2020ReblogShareTweetShareCompany Raises $145 Million in Eighteen Months to Complete Development and Early Commercialization of Breakthrough DNA Sequencing PlatformSAN DIEGO, Jan. 9, 2020 /PRNewswire/ -- Omniome, Inc., developer of an innovative DNA sequencing platform capable of delivering unsurpassed sequencing accuracy, today announced it has raised an additional $60 million with the completion of its Series C financing. The funding round was led by Madrone Capital Partners. Current investors include ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Sciences Ventures, Nan Fung Life Sciences and others.OmniomeMoreThe company, which raised $60 million in financing in mid-2018, will utilize the new $60 million equity financing in addition to previous debt financing in order to accelerate late-stage product development and launch planning."Our product development efforts are advancing rapidly and shifting towards delivering our first beta prototype instruments," said Dave Mullarkey, President and CEO at Omniome. "We welcome Madrone and appreciate ongoing support from our current investors in executing on our plans."The company will deploy portions of the financing proceeds to expand the company's capabilities by hiring new team members across multiple disciplines, particularly in manufacturing, engineering, development, customer support and commercial. The company will continue to optimize its proprietary technology while accelerating instrument development and delivery of commercially-impactful sequencing platforms."Omniome has made incredible progress over the past couple years maturing from an early product concept company to a late stage product development company," said Ken Song, M.D., Omniome's Executive Chairman. "The goal and vision have always been to develop a disruptive sequencing technology taking into account accuracy, speed, throughput, and cost. The team's success in advancing product development across these dimensions has attracted considerable interest from top tier investors."About Omniome Omniome is developing a breakthrough DNA sequencing platform capable of delivering unsurpassed sequencing accuracy with the potential to advance cancer diagnostics, drive high fidelity single-cell applications and broadly support clinical sequencing. Our proprietary scar-free sequencing biochemistry and technology provides enhanced precision and flexibility. To learn more about Omniome, please visit our website at www.omniome.com.Contact:Kelly Perezkperez@omniome.com (858) 832-2303CisionMoreView original content to download multimedia:http://www.prnewswire.com/news-releases/omniome-closes-60-million-series-c-financing-to-advance-novel-genomic-sequencing-platform-300984052.htmlSOURCE Omniome, Inc.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextWhy BE Group AB (publ) (STO:BEGR) Is A Dividend RockstarSimply Wall St.Does JNBY Design (HKG:3306) Have A Healthy Balance Sheet?Simply Wall St.Risk-Averse Investors May Buy These 5 Low Leverage StocksZacksDow (DOW) Declares Completion of Senior Notes OfferingZacksDo Bernie’s Numbers Add Up? Bond Market Says They Don’t Need ToBloombergBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoSalMar ASA Annual Results: Here's What Analysts Are Forecasting For Next YearSimply Wall St.'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video